依奇珠单抗：全球首次获批。
Ixekizumab: First Global Approval.
机构信息
Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.
出版信息
Drugs. 2016 May;76(8):901-5. doi: 10.1007/s40265-016-0579-y.
Ixekizumab (Taltz(®)) is a humanised monoclonal immunoglobulin G antibody developed by Eli Lilly and Company that has been approved in the USA as a treatment for plaque psoriasis. Ixekizumab is a specific inhibitor of interleukin-17A (IL-17A), a pro-inflammatory cytokine that has a role in the development of several inflammatory conditions. This article summarizes the milestones in the development of ixekizumab leading to this first approval for plaque psoriasis.
依奇珠单抗（Taltz(®)）是一种由礼来公司开发的人源化单克隆免疫球蛋白 G 抗体，已获美国批准用于治疗斑块型银屑病。依奇珠单抗是白细胞介素-17A（IL-17A）的特异性抑制剂，IL-17A 是一种促炎细胞因子，在几种炎症性疾病的发生发展中起作用。本文总结了依奇珠单抗的开发历程中的重要里程碑，最终使其首次获批用于斑块型银屑病。
Zotero 插件